Levin Capital Strategies, L.P. Gamida Cell Ltd. Call Options Transaction History

Levin Capital Strategies, L.P.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 06, 2024	SELL	$0.25 - $1.02 $10,775 - $43,962	-43,100 Reduced 29.32%	103,900 $42,000
Q3 2023 Oct 31, 2023	SELL	$0.85 - $1.87 $85,425 - $187,935	-100,500 Reduced 40.61%	147,000 $151,000
Q2 2023 Jul 31, 2023	BUY	$0.73 - $2.37 $82,125 - $266,625	112,500 Added 83.33%	247,500 $477,000
Q1 2023 Apr 24, 2023	BUY	$0.68 - $1.71 $91,800 - $230,850	135,000 New	135,000 $109,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Levin Capital Strategies, L.P., based on Form 13F filings with the SEC.

Stay updated on Levin Capital Strategies, L.P. with notifications on news.